1. Comparison of median survival: any single agent vs. any combination.
| Study | Single agent | Combination | ||||
| n | Median OS (months) |
Median PFS (months) |
n | Median OS (months) |
Median PFS (months) |
|
|
Alberts 1987 C vs. MC vs. MVBC |
9 | 17 (C) | nr | 54 (MVBC) 51 (MC) |
6.9 (MVBC) 7 (MC) |
5.4 (MVBC) 7.2 (MC) |
|
Bezwoda 1986 H vs. CMeth |
13 | 4 (H) | nr | 37 | 9 (CMeth) | nr |
|
Cadron 2005 C vs. CIF |
11 | 13 (C) | nr | 10 | 12.3 (CIF) | nr |
|
Greenberg 1977 A vs. AB |
9 | 4 (A) | nr | 11 | 4.3 (AB) | nr |
|
Long 2005 C vs. CTop vs. MVAC |
146 | 6.5 (C) | 2.9 (C) | 63 (MVAC) 147 (CTop) |
9.4 (MVAC) 9.4 (CTop) |
4.4 (MVAC) 4.6 (CTop) |
|
Malkasian 1981 A vs. VF |
20 | 5.9 (A) | 2.8 (A) | 21 | 9 (VF) | 2.9 (VF) |
|
Moore 2004 C vs. CP |
134 | 8.9 (C) | 3 | 130 | 9.9 (CP) | 4.9 |
|
Omura 1981 cyclo vs. AFV |
30 | 6.5 (cyclo) | nr | 31 | 7.6 (AFV) | nr |
|
Omura 1997 C vs. CMito vs. CI |
140 | 8 (C) | 3.2 | 147 (CMito) 151 (CI) |
7.3 8.3 |
nr (CMito) 4.6 (CI) |
|
Wallace 1978 A vs. AV vs. Acyclo |
63 | 5.9 (A) | 3.3 | 63 (AV) 52 (Acyclo) |
5.5 (AV) 7.3 (Acyclo) |
3.4 (AV) 3.9 (Acyclo) |
A: adriamycin; AB: adriamycin/bleomycin; Acyclo: adriamycin/cyclophosphamide; AFV: adriamycin/5‐fluorouracil/vincristine; AV: adriamycin/vincristine; C: cisplatin; CI: cisplatin/ifosfamide; CIF: cisplatin/ifosfamide/5‐fluorouracil; CMeth: cisplatin/methotrexate; CMito: cisplatin/mitolactol; CP: cisplatin/paclitaxel; CTop: cisplatin/topotecan; cyclo: cyclophosphamide; H: hydroxyurea; M: mitomycin; MC: mitomycin/cisplatin; MVAC: methotrexate/vinblastine/doxorubicin/cisplatin; MVBC: mitomycin/vincristine/bleomycin/cisplatin; nr: not reported; OS: overall survival; PFS: progression‐free survival; VF: vincristine/5‐fluorouracil.